Immunogenicity of cyclophosphamide-treated tumor cells.
作者信息
Kawalec M, Skórski T, Hoser G
机构信息
Medical Center of Postgraduate Education, Department of Cytophysiology, Warsaw.
出版信息
Arch Immunol Ther Exp (Warsz). 1988;36(3):345-50.
PMID:3250356
Abstract
The immunogenicity of cyclophosphamide-treated murine tumor cells was tested on syngeneic or semisyngeneic mice. The majority of mice immunized with modified Ehrlich carcinoma cells, L1210 leukemia cells or AA sarcoma cells survived after challenge with a lethal dose of unmodified tumor cells. Plasmacytomas RPC-5 and MOPC 104E were less immunogenic and L-1 sarcoma cells were not immunogenic.
摘要
相似文献
1
Immunogenicity of cyclophosphamide-treated tumor cells.
Arch Immunol Ther Exp (Warsz). 1988;36(3):345-50.
2
3
4
Immunogenicity of tumor cells modified by trinitrobenzene suflonic acid (TNBS).经三硝基苯磺酸（TNBS）修饰的肿瘤细胞的免疫原性。
Prog Clin Biol Res. 1976;9:109-21.
5
Cyclophosphamide-adriamycin combination chemotherapy of transplantable murine tumors.环磷酰胺-阿霉素联合化疗对可移植性小鼠肿瘤的作用
Cancer Res. 1975 Jun;35(6):1568-73.
6
Development of resistance to MOPC-315 plasmacytoma after intralesional and intraperitoneal melphalan therapy of tumor-bearing BALB/c mice. I. Enhancement of in vivo rejection responses by combined chemotherapy-immunotherapy.荷瘤BALB/c小鼠经瘤内和腹腔注射美法仑治疗后对MOPC-315浆细胞瘤耐药性的发展。I. 联合化疗-免疫疗法增强体内排斥反应
J Natl Cancer Inst. 1982 Jun;68(6):963-9.
7
Cyclophosphamide- or ifosfamide-treated L 1210 leukaemia cells: immunogenicity, viability and metabolism.环磷酰胺或异环磷酰胺处理的L1210白血病细胞：免疫原性、活力和代谢
Folia Biol (Praha). 1986;32(5):354-65.
8
9
Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro.通过体外主要致敏的细胞对已建立的同基因白血病进行过继性治疗。
Cancer Res. 1981 Jul;41(7):2658-63.
Zotero 插件